HPG axis stimulation in men
Dhillo 2005 was the first human study to show that kisspeptin-54 administration significantly increases plasma LH, FSH, and testosterone in healthy men. Subsequent work has demonstrated similar effects in hypogonadotropic populations, with kisspeptin agonists being developed as fertility-preserving alternatives to testosterone replacement therapy.
4 human studies · 12 animal studies
Key findings & citations
- Kisspeptin-54 acutely raises LH, FSH, and testosterone in healthy men.
- Effects preserved in hypogonadotropic populations.
- Drug-development pipeline (TAK-448, others) targets fertility-preserving androgen restoration.
Top citations
Our take
Mechanistically a real, fertility-preserving way to raise testosterone. Approved kisspeptin therapeutics don't yet exist — most clinical-grade kisspeptin remains research-only.